1. Home
  2. INCR vs ICCM Comparison

INCR vs ICCM Comparison

Compare INCR & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.86

Market Cap

47.4M

Sector

Health Care

ML Signal

HOLD

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.23

Market Cap

41.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
ICCM
Founded
1994
2006
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4M
41.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
INCR
ICCM
Price
$0.86
$0.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$2.50
AVG Volume (30 Days)
26.8K
641.0K
Earning Date
05-01-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
$139.51
Revenue Next Year
$41.75
$75.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.22
52 Week High
$1.77
$1.40

Technical Indicators

Market Signals
Indicator
INCR
ICCM
Relative Strength Index (RSI) 56.86 32.89
Support Level $0.86 N/A
Resistance Level $0.89 $0.74
Average True Range (ATR) 0.04 0.02
MACD 0.00 0.01
Stochastic Oscillator 75.33 16.19

Price Performance

Historical Comparison
INCR
ICCM

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: